3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A deep-dive into the economic modeling, cost-per-QALY estimates, payer-coverage implications, and individual patient value calculations derived from the ELITE trial of oral estradiol in early versus late menopause.
A detailed examination of the ELITE trial's enrollment biases, statistical caveats, generalizability gaps, and what peer commentary revealed about this landmark early-HRT study.
How the ELITE trial's timing hypothesis for estradiol and atherosclerosis should reshape HRT prescribing decisions, guideline updates, and patient selection today.